Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MD-0727 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MD-0727 | DRUG | - |
Inclusion Criteria: * Patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age * Patient must agree to use contraception and/or birth control if sexually active * Patient may not be on lipid-lowering therapies at least 6 weeks prior to study and must have a fasting LDL-C ...
MD-0727 is an investigational small molecule being developed for the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MD-0727 is being developed by Ironwood Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IRWD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with hypercholesterolemia.
MD-0727 is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 2 clinical trial has been completed, and the drug is not currently in active clinical trials.
MD-0727 has been studied in one completed Phase 2 clinical trial, identified as NCT00404001. This trial, titled 'Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia,' enrolled 150 participants in the United States and was a randomized, double-blind study.
MD-0727 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 2 trial (NCT00404001) evaluated the drug in patients with hypercholesterolemia, but the drug has not yet been approved for any use.